William Blair Comments on Zoetis’ Q2 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – William Blair lifted their Q2 2025 earnings estimates for Zoetis in a research note issued to investors on Tuesday, May 6th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $1.62 per share for the quarter, up from their prior estimate of $1.59. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. William Blair also issued estimates for Zoetis’ Q3 2025 earnings at $1.65 EPS, Q4 2025 earnings at $1.50 EPS, FY2025 earnings at $6.26 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.78 EPS, Q3 2026 earnings at $1.79 EPS, Q4 2026 earnings at $1.63 EPS and FY2026 earnings at $6.80 EPS.

Other equities analysts have also issued research reports about the stock. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday. Piper Sandler lifted their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $212.13.

Zoetis Price Performance

ZTS stock opened at $159.96 on Friday. The stock has a market capitalization of $71.37 billion, a price-to-earnings ratio of 29.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis has a 52-week low of $139.70 and a 52-week high of $200.33. The stock’s fifty day simple moving average is $157.27 and its 200-day simple moving average is $166.06.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.38 earnings per share.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,862 shares of company stock valued at $312,254. Corporate insiders own 0.18% of the company’s stock.

Institutional Trading of Zoetis

Several institutional investors have recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC raised its stake in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at approximately $30,000. Cornerstone Planning Group LLC lifted its stake in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after purchasing an additional 120 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.